Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYNFLU001
- Development stage
- Phase 1
- Lead developer
- Mynvax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**MYNFLU001** is an investigational, adjuvanted quadrivalent recombinant influenza protein-subunit vaccine developed by Mynvax for prevention of seasonal influenza. The vaccine contains recombinant hemagglutinin derivatives from World Health Organization-recommended seasonal influenza strains and is produced in insect cells. It is intended to induce protective immune responses against influenza hemagglutinin, the major viral surface glycoprotein responsible for host-cell attachment and membrane fusion. MYNFLU001 has entered Phase 1 clinical development, including a randomized, double-blind, placebo-controlled study in healthy adults. ([mynvax.com](https://www.mynvax.com/influenza.html))
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on MYNFLU001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYNFLU001.